Advertisement
Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer,stated, "We are very pleased to receive FDA clearance for the use of ourPlexur P(TM) product in the spine. We continue to receive many favorablecomments from orthopedic surgeons about the efficacy of Plexur P(TM) and wewill immediately offer our Plexur P(TM) product to spine surgeons supported bythe clinical information and experience we have gained over the last year.Our proprietary Plexur(R) Technology continues to be one of the keys to ourproduct pipeline and future growth initiatives."
Advertisement
To date, the Plexur P(TM) Biocomposite has been used by a variety ofsurgeons in tibial plateau fractures, tibial osteotomies and a variety of footand ankle procedures, and can now be used in the spine. Our Plexur P(TM)product can be combined with our proprietary Grafton(R) DBM, local bone or ournew Kinesis(TM) BMAC(TM) cellular system. Plexur P(TM) is available asgranules, cylinders, blocks, wedges and sheets. For more information aboutthe Plexur P(TM) Biocomposite, please go to our websites athttp://www.plexur.com or http://www.osteotech.com.
The Plexur(R) Technology uses bone tissue for procedure specific surgicalapplications in combination with a wide variety of polymers. On a world-widebasis, Osteotech controls over 33 patents and over 65 pending patentapplications covering this technology for human and xenograft bone tissue.
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a globalleader in providing OsteoBiologic solutions for regenerative medicine tosupport surgeons and their patients in the repair of the musculoskeletalsystem through the development of innovative therapy-driven products thatalleviate pain, promote biologic healing and restore function. For furtherinformation regarding Osteotech or this press release, please go toOsteotech's website at http://www.osteotech.com.
Certain statements made throughout this press release that are nothistorical facts contain forward-looking statements (as such are defined inthe Private Securities Litigation Reform Act of 1995) regarding the Company'sfuture plans, objectives and expected performance. Any such forward-lookingstatements are based on assumptions that the Company believes are reasonable,but are subject to a wide range of risks and uncertainties and, therefore,there can be no assurance that actual results may not differ materially fromthose expressed or implied by such forward-looking statements. Factors thatcould cause actual results to differ materially include, but are not limitedto, the Company's ability to develop and introduce new products, differencesin anticipated and actual product and service introduction dates, the ultimatesuccess of those products in the marketplace, the continued acceptance andgrowth of current products and services, the impact of competitive productsand services, the availability of sufficient quantities of suitable donatedtissue and the success of cost control and margin improvement efforts. Certainof these factors are detailed from time to time in the Company's periodicreports filed with the Securities and Exchange Commission. All information inthis press release is as of April 25, 2008 and the Company does not intend toupdate this information.
SOURCE Osteotech, Inc.
